News coverage about Penumbra (NYSE:PEN) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Penumbra earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.2636710410872 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
Shares of PEN opened at $120.60 on Friday. The firm has a market cap of $4,041.11, a PE ratio of -12,060.00, a P/E/G ratio of 43.05 and a beta of 0.01. Penumbra has a 1-year low of $77.75 and a 1-year high of $127.40.
Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The firm had revenue of $96.05 million for the quarter, compared to analyst estimates of $87.69 million. Penumbra had a net margin of 1.40% and a negative return on equity of 0.23%. analysts predict that Penumbra will post 0.14 EPS for the current fiscal year.
Several equities analysts have issued reports on the stock. William Blair assumed coverage on shares of Penumbra in a report on Wednesday, February 21st. They issued an “outperform” rating on the stock. Goldman Sachs assumed coverage on shares of Penumbra in a report on Wednesday. They issued a “buy” rating and a $145.00 price target on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $125.00 price target on shares of Penumbra in a report on Thursday. BMO Capital Markets lifted their price target on shares of Penumbra from $110.00 to $115.00 and gave the stock a “market perform” rating in a report on Wednesday, February 28th. Finally, Zacks Investment Research lowered shares of Penumbra from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $130.75.
In other news, insider Daniel Donen Davis sold 30,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $88.80, for a total transaction of $2,664,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Don W. Kassing sold 2,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $100.94, for a total transaction of $201,880.00. Following the sale, the director now directly owns 2,648 shares in the company, valued at $267,289.12. The disclosure for this sale can be found here. Insiders have sold 60,000 shares of company stock worth $6,062,277 over the last three months. Corporate insiders own 13.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Penumbra (PEN) Share Price” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-penumbra-pen-share-price.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.